Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$65.42 USD
+0.15 (0.23%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $65.42 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Gilead Sciences, Inc. [GILD]
Reports for Purchase
Showing records 501 - 520 ( 521 total )
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
EASL 2010 Preview Part I.Summary of Oral Presentations.
Provider: WEDBUSH SECURITIES INC.
Analyst: XU K
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Quad vs. Atripla Hard to Tell from CROI
Provider: WEDBUSH SECURITIES INC.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Presents Detailed Quad Pill and GS 9350 Data - at CROI; Maintain Neutral
Provider: Merriman Curhan Ford & Co.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Quad Pill Abstracts for CROI Meeting for Quad Pill Released; Maintain Neutral
Provider: Merriman Curhan Ford & Co.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: MERRIMAN CURHAN FORD & CO.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet.
Provider: MERRIMAN CURHAN FORD & CO.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Above industry average growth prospects & expected near term pipeline upsides keep growth story intact
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Q4:09 Beats on Both Top and Bottom Line; 2010 Guidance Ahead of Current Consensus
Provider: WEDBUSH SECURITIES INC.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Reports 4Q09 Earnings; Maintain Neutral
Provider: MERRIMAN CURHAN FORD & CO.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Q4:09 Preview
Provider: WEDBUSH SECURITIES INC.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: MERRIMAN CURHAN FORD & CO.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Previewing 4Q09:What to Watch for in 2010; Maintain Neutral
Provider: MERRIMAN CURHAN FORD & CO.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Life Sciences - Biotechnology - Biotech Balance Sheet
Provider: MERRIMAN CURHAN FORD & CO.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: MERRIMAN CURHAN FORD & CO.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Topline Phase II Quad vs. Atripla Meets Expectations
Provider: WEDBUSH SECURITIES INC.